science wire

English-language edition of Jena University's research magazine LICHTGEDANKEN follows scientists in their search for tailor-made drugs and targeted therapies Light Life Liberty Inflammatory diseases,

Roche and Spark Therapeutics, Inc.

Yale University and Mayo Clinic have been awarded a grant for up to $5.3 million over two years by the U.S. Food and Drug Administration (FDA) to study patients' experiences with pain and use of opioids prescribed for acute pain. This project is part of the Center of Excellence in Regulatory Science and Innovation (CERSI) , a joint effort between Yale, Mayo Clinic, and the FDA.

Ever wondered what micro-organisms are living on your skin? Drop into our interactive lab in the heart of Cardiff's busy shopping centre to find out, and you can even get pictures of them! Cardiff Un

Lucentis (ranibizumab), if approved in the EU for this indication, will be the first and only pharmacological therapy for ROP in these vulnerable infants Positive opinion is based on the landmark Pha

Decision based on results from first Phase III study to show a cancer immunotherapy-based combination significantly improved overall survival (OS) and progression-free survival (PFS) in over 20 years

University of Birmingham researchers, with industry partners including health technology companies Dignio and Datatrial, have been awarded £1.1 million by UK Research & Innovation (UKRI)'s Innovate UK, to investigate patients' experience of cell and gene therapies.

FDA grants crizanlizumab Priority Review based on Phase II data showing prevention of vaso-occlusive crises (VOCs) in patients with sickle cell disease, shortening FDA review to six months from stand

University of Birmingham researchers are leading the way with a ground-breaking role to enable more children with the rare cancer neuroblastoma to access potentially life-saving clinical trials more quickly.

New analyses from phase III HAVEN studies support Hemlibra's sustained efficacy, safety and quality of life benefit in people with haemophilia A, with and without factor VIII inhibitors First data of

Recommendation based on the results of IMpassion130 study in triple-negative breast cancer, an aggressive type of breast cancer with high unmet medical need First positive Phase III cancer immunother

Professor Jeffrey Hill has been appointed as the new Director of the Sussex Drug Discovery Centre ( SDDC ) within the School of Life Sciences.

U.S. hospitals wait over a year on average to begin prescribing newly developed antibiotics, a delay that might threaten the supply or discourage future development of needed drugs.

A new Imperial centre will pioneer research to optimise how antimicrobial drugs are used to both improve patient care and preserve antibiotics.

The young spin-off "P4 Therapeutics" was awarded with the "Der Brutkasten Media Award" An interdisciplinary team of the University of Vienna and the Medical University of Vienna has developed a new platinum compound with great potential as anticancer drug.

University of Queensland experts are available to comment on various issues relating to MND Global Day on Friday 21 June.

First tumour-agnostic medicine approved in Japan for adult and paediatric patients with NTRK fusion-positive advanced recurrent solid tumours Approval supported by the data mainly from the pivotal Ph

For the first time efficacy and safety data from dedicated phase III trials are analyzed together in one abstract, backing Cosentyx as comprehensive treatment across multiple manifestations of psoria

Data show switching to Hyrimoz (biosimilar adalimumab) from the reference medicine provides sustained efficacy with no new safety concerns in patients with moderate-to-severe rheumatoid arthritis   A

Results from two Phase II trials, ENESTfreedom and ENESTop, support and extend previous findings of long-term durability of molecular response after stopping Tasigna, reducing time on drug for many C

First-of-its-kind data shows efficacy and safety of a biologic in the management of axial manifestations of psoriatic arthritis (PsA), which affect up to an estimated 35 million people worldwide   66

Almost 90% of patients had no radiographic progression of psoriatic arthritis (PsA) at 2 years with Cosentyx (secukinumab) 300mg   Data at 2 years demonstrate over 50% of adults with active PsA achie

Artery hardening happens to everyone as they age..but up until now we haven't known what controls this process and therefore how to treat it Melinda Duer New approach to drug discovery could l

New targeted medicine shown to improve clinical outcomes in people with relapsed or refractory diffuse large B-cell lymphoma compared to a commonly used regimen First-in-class antibody-drug conjugate

Roche and Spark Therapeutics, Inc.

The deaths of thousands of women from bleeding after childbirth could be prevented by a new drug which does not need to be stored in a refrigerator, according to research conducted in collaboration with the University of Birmingham.

Advanced Accelerator Applications Receives Positive CHMP Opinion for LysaKare for Reduction of Kidney Exposure to Radiation During Peptide Receptor Radionuclide Therapy with Lutetium ( 177 Lu) Oxodot

Five-year Tafinlar + Mekinist survival data presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting and published simultaneously in The New England Journal of Medicine   Results are from the largest dataset and longest follow-up of more than 500 patients with BRAF-mutated metastatic melanoma, a genetic mutation common for this aggressive skin cancer   Additional Novartis melanoma research presented at ASCO includes effi

Venclexta/Venclyxto plus Gazyva/Gazyvaro showed improvements across multiple efficacy measures compared to Gazyva/Gazyvaro plus chlorambucil, including progression-free survival and deep remissions a

There are no approved treatment options for patients with advanced bladder cancer after they've received standard chemotherapy and immune treatments, but the results of a phase II clinical trial led

Roche data from 17 breast cancer abstracts presented at this year's meeting An overall survival improvement was observed with Tecentriq and nab-paclitaxel in PD-L1-positive metastatic triple-negative